Form 4: BioXcel CEO Vimal Mehta Reports Stock Acquisitions

BioXcel Therapeutics CEO and President Vimal Mehta reported the acquisition of common stock through the conversion of Restricted Stock Units.

Summary

• Vimal Mehta, CEO and President of BioXcel Therapeutics, Inc. (BTAI), acquired 164 shares of common stock on March 14, 2026, and 219 shares on March 15, 2026.
• These acquisitions resulted from the conversion of Restricted Stock Units (RSUs) at a price of $0 per share.
• Following these transactions, Vimal Mehta directly beneficially owns 21,259 shares of common stock.
• Indirect beneficial ownership includes 125 shares held by a spouse and 480,343 shares held by BioXcel LLC.
• Remaining derivative securities include 1,532 Restricted Stock Units.
• The RSUs granted on March 14, 2022 (2,609 units) and March 15, 2023 (3,500 units) vest 25% on their first anniversary and 6.25% each successive three-month period, contingent on continuous employment.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It represents a routine compensation-related acquisition of shares by an insider, reinforcing their equity stake in the company without indicating new strategic moves or significant financial performance changes.

Positives

• The acquisition of common stock by the CEO, even through RSU conversion, indicates continued insider ownership and alignment with shareholder interests.
• The vesting schedule for RSUs incentivizes long-term commitment and performance from the CEO.

Risks

• The vesting of Restricted Stock Units is subject to the Reporting Person's continuous employment with the Issuer, meaning unvested units could be forfeited upon termination.

Industry Context

StockSavvy.ai notes that insider transactions, such as the conversion of Restricted Stock Units into common stock, are routine compensation events. While not typically a strong market mover, they are monitored by investors as they reflect management's ongoing equity stake and commitment to the company.

Related Party Transactions

• Vimal Mehta indirectly beneficially owns 480,343 shares of common stock held by BioXcel LLC. He is an executive officer and one of two managers on the board of managers of BioXcel LLC and BioXcel Holdings, Inc. (Parent), and the sole member of the board of directors of Parent. He disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders will observe the CEO's continued equity ownership, which can be a positive signal of alignment between management and shareholder interests.

Next Steps

• Continued vesting of the remaining Restricted Stock Units according to their respective schedules, contingent on the CEO's continuous employment.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to the vesting and conversion of Restricted Stock Units. While it shows continued insider ownership, it does not present new information that would significantly alter the investment thesis for BioXcel Therapeutics. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial updates.

Keywords

BTAI, BioXcel Therapeutics, Vimal Mehta, Insider Transaction, Form 4, Restricted Stock Units, RSU, Common Stock, Beneficial Ownership